UPDATE News
Gain Therapeutics Secures FDA IND Clearance for AI-Designed GT-02287
Gain Therapeutics, a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application for GT-02287. This c
Aidoc's AI for Radiology Reports Gets FDA Breakthrough Designation
Aidoc has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its "First Read" AI system. This AI tool analyzes chest radiographs and generates preliminary radiology r
10x Genomics Q1 Beat & AI Drug Discovery Positioning
10x Genomics reported Q1 results surpassing revenue and earnings estimates, with strong uptake of new single-cell and spatial consumables like FLEX Apex and Atara. The company is positioning its expan
MedSyntra Bolsters Healthcare AI Vision with New Board Appointment
MedSyntra, a company at the intersection of healthcare, AI, and sovereign medical data infrastructure, announced the appointment of Dr. George Syrmalis to its Board of Directors. This move strengthens
Sanofi Invests $294M to Expand Toronto AI Center of Excellence
Sanofi is making a significant investment of $294 million to expand its global Artificial Intelligence (AI) Centre of Excellence in Toronto. This initiative, supported by a conditional grant from the
AI Aids Pancreatic Cancer Detection, New Drug Fast-Tracked by FDA
Fox News reported on two significant advancements offering new hope in the fight against pancreatic cancer. The FDA has fast-tracked daraxonrasib, an investigational drug by Revolution Medicines, whic
CorTec BCI System Enables Stroke Patient to Control Computer with Mind
CorTec GmbH announced that the first participant in a clinical trial successfully controlled a computer through thought alone using their Brain Interchange™ BCI system. This fully implanted, wireless
Intellia Files for FDA Approval of CRISPR Gene-Editing Therapy
Intellia Therapeutics has filed for FDA approval of its CRISPR-based medicine, lonvo-z, following positive preliminary Phase 3 clinical trial data. The therapy demonstrated a significant reduction in
Neuralink Targets High-Volume Brain Implant Production by 2026
Elon Musk's neurotechnology company, Neuralink, is planning to scale up production of its brain-computer interface (BCI) devices. The company aims for high-volume manufacturing and fully automated sur
OpenEvidence Reaches 1M Daily AI Clinical Consultations
OpenEvidence has achieved a historic milestone of one million clinical consultations between NPI-verified physicians and its AI system within a single 24-hour period on March 10, 2026. This accomplish
3billion Showcases AI-Powered Variant Interpretation Platform GEBRA
3billion, a leader in AI-powered rare disease diagnostics, is showcasing its proprietary SaaS-based variant interpretation platform, GEBRA, at the 2026 American College of Medical Genetics and Genomic
How Lilly Used AI To Crank Up Production Of Its Popular GLP-1s
Eli Lilly has successfully utilized AI, specifically digital twin technology, to optimize the manufacturing process of its popular GLP-1 drugs, Zepbound and Mounjaro. This AI-driven approach significa
Recursion's AI Drug Discovery Platform Achieves Clinical & Sanofi Milestones
Recursion Pharmaceuticals has reported its first positive clinical proof-of-concept for REC-4881 in familial adenomatous polyposis, demonstrating tangible results from its AI-driven drug discovery app
MindRank Doses First Patient in Phase III AI-Designed GLP-1RA Trial
MindRank, an AI-driven drug discovery company, has dosed the first patient in its Phase III clinical trial for MDR-001, an AI-designed oral GLP-1 receptor agonist for obesity and type 2 diabetes in Ch
Recursion Makes the Unknown Known in Rare Disease Drug Discovery
Dr. Najat Khan, the new CEO of Recursion, is steering the company's focus towards demonstrating clinical outcomes in AI-driven drug discovery. This shift is underscored by recent positive data from th